Results from a phase 3 trial indicated that olaparib yielded better-preserved health-related quality of life and reduced pain burden vs the control for patients with homologous recombination repair gene–altered metastatic castration-resistant prostate cancer who progressed following a prior next-generation hormonal drug.
Findings from a post-hoc analysis identified disparities in Black patients with early hormone receptor–positive breast cancer that could not be explained by early discontinuation of endocrine therapy, clinicopathologic characteristics, insurance coverage, or neighborhood deprivation index.
Nisha Joseph, MD, presents the case of a 78-year-old man with transplant-ineligible multiple myeloma and discusses treatment strategy.
Experts discuss how they define frail and high-risk patients with multiple myeloma and their treatment approaches for these patient populations.
Breast cancer mortality could be reduced by half for patients with ATM, CHEK2, and PALB2 pathogenic variants who undergo annual MRI screenings between the ages of 30 to 35 years and annual MRI screenings and mammography for those 40 or older.
Stacy A. Cohen, MD, and Mark Lewis, MD, discuss how DFS correlates with stage and adjuvant chemotherapy receipt in patients who are ctDNA-positive.
A physician explains why he doesn’t believe there is a “typical” patient and why advanced RCC therapies must be tailored to each case.
GI oncologists discuss DFS data from the dynamics analysis cohort of the GALAXY study.
To close the discussion, panelists reflect on their practices’ guidance on long-acting antibody prophylaxis and vaccination against COVID-19 for patients with graft-versus-host-disease (GVHD).